SeraCare Life Sciences Inc (SRLS), develops and manufactures the highest quality, biologically-based products, announced on Monday that it had agreed to accept the acquisition by the Chicago private equity firm Linden Capital Partners at the price of $4 per share offer, which is 19% higher than the SeraCare stock closing price of $3.37 on Friday, a premium of 25% compared with the 30 days weighted average of the SeraCare stock.
This transaction has been approved by the Board of Directors, it would need to get the company’s shareholders and regulator’s approvals. Linden has arranged financing for the acquisition.